| Page 55 | Kisaco Research
 

Polyxeni Kyriopoulou

Head of Legal
Elpen Pharmaceuticals

Polyxeni Kyriopoulou

Head of Legal
Elpen Pharmaceuticals

Polyxeni Kyriopoulou

Head of Legal
Elpen Pharmaceuticals
 

Lena Moran-Adams

Group General Counsel
-

Lena Moran-Adams

Group General Counsel
-

Lena Moran-Adams

Group General Counsel
-
 

Jennifer Ulbrich

Senior Legal Counsel
Roche

Jennifer Ulbrich

Senior Legal Counsel
Roche

Jennifer Ulbrich

Senior Legal Counsel
Roche
 

David Lawless

Senior Director, Assistant General Counsel
Regeneron

David Lawless

Senior Director, Assistant General Counsel
Regeneron

David Lawless

Senior Director, Assistant General Counsel
Regeneron
 

Daphné Derouane

Associate General Patent Counsel
UCB

Daphné DEROUANE is a qualified European Patent Attorney and holds a Ph.D. in Organic Chemistry from UCLouvain in Belgium. She has over 25 years of experience as in-house patent counsel in industry. Currently, she serves as Associate General Patent Counsel at UCB Biopharma in Belgium, where she leads the IP support for the Research Organization.

Daphné Derouane

Associate General Patent Counsel
UCB

Daphné Derouane

Associate General Patent Counsel
UCB

Daphné DEROUANE is a qualified European Patent Attorney and holds a Ph.D. in Organic Chemistry from UCLouvain in Belgium. She has over 25 years of experience as in-house patent counsel in industry. Currently, she serves as Associate General Patent Counsel at UCB Biopharma in Belgium, where she leads the IP support for the Research Organization.

Her expertise encompasses defining the overall IP strategy of UCB’s early-stage assets and technologies, patent drafting & prosecution, providing freedom-to-operate opinions, and the negotiation of a variety of agreements. She also closely monitors external IP developments which are relevant to the pharmaceutical industry to ensure the UCB IP strategies remain fit-for-purpose.

 

Cornelia Keller

VP & General Counsel
Merz Therapeutics

Cornelia Keller

VP & General Counsel
Merz Therapeutics

Cornelia Keller

VP & General Counsel
Merz Therapeutics
 

Charles Sermon

Co-Founder, General Counsel & Business Development
Mereo BioPharma

Charles Sermon

Co-Founder, General Counsel & Business Development
Mereo BioPharma

Charles Sermon

Co-Founder, General Counsel & Business Development
Mereo BioPharma
 

Caroline Stockwell

VP, Head of Legal & Associate General Counsel
Amicus Therapeutics

Caroline Stockwell

VP, Head of Legal & Associate General Counsel
Amicus Therapeutics

Caroline Stockwell

VP, Head of Legal & Associate General Counsel
Amicus Therapeutics
 

Andrew Berry

Director, Claims Administration & Payment Integrity
Humana

Andrew Berry

Director, Claims Administration & Payment Integrity
Humana

Andrew Berry

Director, Claims Administration & Payment Integrity
Humana
 

Jennifer Dupee

Deputy Director, Center for Program Integrity
Centers for Medicare & Medicaid Services

Jennifer Dupee has served as a senior leader at CMS for more than a decade and was recently appointed Deputy Director of the Center for Program Integrity (CPI), a role in which she leads CPI’s mission to crush fraud, waste, and abuse across Medicare, Medicaid and the Marketplace. Under Jennifer's leadership, CPI will continue fundamentally transforming how CMS fights fraud.

Jennifer Dupee

Deputy Director, Center for Program Integrity
Centers for Medicare & Medicaid Services

Jennifer Dupee

Deputy Director, Center for Program Integrity
Centers for Medicare & Medicaid Services

Jennifer Dupee has served as a senior leader at CMS for more than a decade and was recently appointed Deputy Director of the Center for Program Integrity (CPI), a role in which she leads CPI’s mission to crush fraud, waste, and abuse across Medicare, Medicaid and the Marketplace. Under Jennifer's leadership, CPI will continue fundamentally transforming how CMS fights fraud. Moving beyond traditional, reactive pay-and-chase models, CPI is executing an offensive, prevention-first strategy that uses advanced data analytics, risk-based targeting, and rapid operational action to stop fraud earlier, at greater scale, and with greater financial impact.